Financial Shenanigans

Financial Shenanigans — RS Technologies (3445)

Forensic risk grade: Watch (38/100). RS Technologies's reported numbers tell a story that is broadly consistent with the underlying business, but three things keep this from a clean grade: (1) a gain on bargain purchase from the RSPDH acquisition flattered reported net income by roughly ¥1.5 billion in FY2024 and ¥0.4 billion in FY2025 — disclosed clearly, but it still inflates the headline EPS comparison; (2) the founder-CEO controls about 44% of shares through a Hong Kong holding vehicle plus a personal stake, with no independent counterweight on the executive side of the board; and (3) ordinary income leans increasingly on Chinese government subsidies routed through Gritek — ¥2.1 billion in FY2025 — that management itself describes as partly non-recurring. Cash flow quality, accruals, and audit governance are clean. The grade would tighten to Clean if FY2026 net income hits the ¥10 billion guide on a like-for-like basis without further negative goodwill or step-up subsidies. It would loosen to Elevated if receivables days creep above 130 again, the SGRS equity loss widens past ¥2 billion, or the next acquisition produces another ¥1 billion+ bargain-purchase gain through net income.

The 13-shenanigan scorecard

The scorecard concentrates the work. The income statement is broadly clean at the operating-income level. The ordinary-income line and net-income line are where the accounting judgment lives. Cash flow quality is genuinely good. Governance has structural concentration but disclosed processes.

Breeding Ground

The breeding ground is moderately elevated — founder concentration combined with M&A-driven growth is the dominant pattern. CEO Nagayoshi Ho (方 永義) controls 35.85% through R.S. TECH HONG KONG LIMITED and another 8.04% personally — roughly 44% combined. The audit-and-supervisory committee structure (監査等委員会設置会社) gives three outside directors a formal role, and KPMG AZSA (あずさ監査法人) audits the company. There is no public history of restatements, auditor resignations, or material weaknesses. The risk is structural rather than evidentiary: there is no independent challenge to the founder on the executive side of the board.

The breeding ground amplifies one specific concern: an M&A-heavy founder-led group that recently produced a ¥1.5 billion gain on bargain purchase has the structural ingredients for accounting drift if discipline slips. The offset is that the audit framework and disclosure quality are functioning — the negative goodwill, the subsidy temporality, and the KPI definition change are all surfaced by management rather than uncovered by analysts.

Earnings Quality

Operating income is faithful; net income is flattered. Operating margin compressed from 22.1% (FY2024) to 18.6% (FY2025) — a real number, no aggressive capitalization gymnastics underneath. The distortion lives below the operating line: a gain on bargain purchase plus Chinese government subsidies make net income and ordinary income look smoother than the underlying trend.

The FY2024 receivables surge (+85% versus revenue +14%) is the single biggest reported red flag on the revenue-recognition test. The DSO chart below clarifies the cause: RSPDH was consolidated on December 31, 2024, so its full receivables balance hit the FY2024 closing balance sheet while only a sliver of its revenue showed up for the year. The FY2025 normalization to 106 DSO (still above the 89-day pre-RSPDH baseline, but well off the 144-day peak) supports management's explanation. If FY2026 DSO trends back to 90–100 days as RSPDH revenue annualizes, this concern fully resolves.

Gross margin has compressed 600bps from the FY2022 peak; operating margin is down 750bps. The compression is consistent with the disclosed mix shift: prime wafer 8-inch ASPs declined ~10% in FY2025, and the lower-margin semi-related/RSPDH segment grew 87% YoY. Headline net income looks resilient (¥9.3B versus ¥9.4B) only because the FY2024 base contained a one-off bargain-purchase gain. This is not a manipulation finding — the income statement is honest — but the visible deceleration is masked by the comparison anchor.

Cash Flow Quality

Cash generation is the strongest signal in the file — clean, well above net income, not reliant on receivable sales or vendor stretch. Three-year CFO / net income runs at 1.58x. There is no evidence of factoring, securitization, or accounts-receivable sales. Vendor payments are not stretched abusively (DPO stable in the mid-60-day range). FCF is positive but modest — ¥4.2 billion FY2024, ¥7.4 billion FY2025 — because growth capex consumed roughly two-thirds of CFO during the recent investment cycle.

Working capital added roughly ¥3.7 billion to FY2025 CFO — meaningful but not a lifeline. AR contracted in absolute terms (RSPDH stabilizing), inventory unwound ¥1.0 billion, and accounts payable extended by ¥1.6 billion. Ex–working capital, CFO would still be ¥11.2 billion against ¥9.3 billion of net income — the underlying conversion remains healthy. There is no sign of supplier-finance arrangements or one-time tax refunds boosting the cash-flow statement.

Metric Hygiene

Two metric-hygiene concerns and one definition change matter. Ordinary income is the metric Japanese investors anchor on, and it is materially flattered by ¥2.1 billion of Chinese government subsidies plus ¥1.0 billion of equity-method losses — the net non-operating contribution is ¥2.4 billion. Operating margin is the cleaner anchor.

The non-operating P&L tells a clean structural story. The FY2024 FX tailwind (¥726M) reversed to a small FX loss in FY2025 (¥88M). The Gritek subsidy doubled to ¥2.1B but is described by management as containing a past-period catch-up — the recurring run rate is probably closer to ¥1.0–1.2B. SGRS equity losses widened to ¥1.08B as the 12-inch China wafer build continues; this is a real cash burn through capital commitments, not just accounting.

What to Underwrite Next

This name belongs in the Watch bucket, not the position-sizing limiter or thesis-breaker buckets. The accounting is faithful at the operating-income level, and the non-operating items that distort net income are clearly disclosed. The forensic posture should be one of disciplined normalization, not skepticism — analyze the business on ex-negative-goodwill, ex-Gritek-subsidy ordinary income, and use operating cash flow rather than net income as the durability anchor.

Five things to monitor over the next four quarters:

1. FY2026 first-half DSO. Pre-RSPDH baseline was 89 days; FY2025 ended at 106. A trend back below 100 days confirms the FY2024 spike was acquisition timing. A drift above 130 days reopens the receivables question.
2. Gritek subsidy in FY2026 ordinary income. Management framed the FY2025 jump (¥1.1B → ¥2.1B) as temporary. A reversion toward ¥1.0–1.2B would be consistent with that framing. A flat or higher number would mean the recurring subsidy stream is structurally larger than disclosed.
3. Negative goodwill in the next M&A. Management has spent ¥10B+ on M&A in the last three years (LE System, RSPDH, planned ~¥36.5B over 2026-2028). If the next acquisition books another ¥1B+ gain on bargain purchase through net income, the pattern of opportunistically priced deals lifting headline EPS becomes a recurring framing concern.
4. SGRS equity loss trajectory. Equity-method losses widened from ¥685M to ¥1,082M as the 12-inch business in China builds. A widening past ¥2B in FY2026 would indicate the 39%-owned affiliate is consuming more capital than the equity stake suggests.
5. Operating margin recovery. FY2025 operating margin compressed 350bps. Management guides FY2026 to ¥84B revenue and ¥15.4B operating profit — implying 18.3% operating margin (vs 18.6% FY2025). The 5-year peak was 26.1% in FY2022. Whether margins stabilize above 18% or continue lower is the cleanest single read on whether the business is structurally maturing or in a cyclical trough.

What would change the grade. A clean FY2026 — ¥10B net income on a like-for-like basis, no further bargain-purchase gains, Gritek subsidy reverting toward ¥1B, DSO below 100 — tightens this to Clean (sub-20). A widening SGRS loss, a new acquisition with another ¥1B+ negative goodwill, or evidence of related-party flow that has not been transparently disclosed in the Japanese yuho moves the grade to Elevated (45-50). The grade does not become a position-sizing limiter unless one of two things happens: a regulator or auditor flag emerges (none today), or the founder-CEO uses related-party transactions to extract value from public shareholders.

Decisive paragraph. RS Technologies's accounting risk is a valuation-input adjustment, not a thesis breaker. The right normalized FY2025 net income is roughly ¥8.9 billion (ex-negative-goodwill), not the reported ¥9.3 billion — a 4% haircut to headline EPS. The right run-rate ordinary income is roughly ¥15.5 billion (ex-Gritek subsidy step-up and ex-FX), not the reported ¥16.6 billion — a 7% haircut. Applying those normalizations leaves screen multiples 4–8% higher than reported. That is the forensic insight that should travel into the valuation model. Position-sizing should respect the founder concentration (44% promoter stake leaves limited float discipline) and the China subsidiary complexity (currency, government, and minority-listing entanglements), but those are governance and structural risks, not accounting deception.